Literature DB >> 12507410

New strategies for prevention of ischemic stroke: the LIFE study.

Harold P Adams1.   

Abstract

New strategies to lower the risk of stroke among high-risk persons are being developed. Therapies such as cholesterol-lowering medications and newer antihypertensive agents appear to complement traditional antithrombotic drugs and surgical procedures. Of particular interest is the use of the newer angiotensin-converting enzyme (ACE) inhibitors, which appear to have an effect on stabilizing the vascular endothelium. The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12507410     DOI： 10.1007/s11910-003-0036-7

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  37 in total

Review 1.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Hypertension and the brain. The National High Blood Pressure Education Program.

Authors:  S J Phillips; J P Whisnant
Journal:  Arch Intern Med       Date:  1992-05

4.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.

Authors:  L Niskanen; T Hedner; L Hansson; J Lanke; A Niklason
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

Review 5.  Evidence-based medicine and ACE inhibition.

Authors:  C Borghi; E Ambrosioni
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

6.  Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.

Authors:  A L Hevener; D Reichart; A Janez; J Olefsky
Journal:  Diabetes       Date:  2001-10       Impact factor: 9.461

7.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

Authors:  M Pyörälä; H Miettinen; P Halonen; M Laakso; K Pyörälä
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial.

Authors:  J A Staessen; L Thijs; J Gasowski; H Cells; R H Fagard
Journal:  Am J Cardiol       Date:  1998-11-12       Impact factor: 2.778

10.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

Authors:  R P Byington; J W Jukema; J T Salonen; B Pitt; A V Bruschke; H Hoen; C D Furberg; G B Mancini
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.